FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to di(arylamino)aryl derivatives presented in the patent claim. The compounds show an inhibitory effect on protein EML4-ALK v1 and protein EGFR kinase activity. Also the invention refers to a pharmaceutical composition containing said compounds, the hybrid protein EML4-ALK and mutant protein EGFR kinase activity inhibitor, the use of said compounds for preparing the pharmaceutical composition, and to a method of preventing or treating non-small-cell lung cancer or EML4-ALK hybrid polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small-cell lung cancer.
EFFECT: use of di(arylamino)aryl as the protein EML4-ALK v1 and protein EGFR kinase activity inhibitors.
12 cl, 95 tbl, 55 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND | 2010 |
|
RU2526253C2 |
| ACRYLANILIDE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN PHARMACOLOGY | 2016 |
|
RU2742372C2 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| NEW PYRIMIDINE DERIVATIVE SUBSTITUTED WITH DEUTERIUM AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2020 |
|
RU2811770C1 |
| NOVEL HETEROCYCLIC SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING INHIBITORY ACTION ON CANCER CELL GROWTH, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2834201C1 |
| PYRIMIDINE-4,6-DIAMINE DERIVATIVE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2022 |
|
RU2834353C2 |
| SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | 2014 |
|
RU2671212C2 |
| CERTAIN CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS | 2014 |
|
RU2718876C2 |
| PYRIMIDINE DERIVATIVE WITH INHIBITORY ACTIVITY ON PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2022 |
|
RU2833427C2 |
| PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | 2012 |
|
RU2598849C2 |
